Franco-Nevada Down Over 8%, on Pace for Largest Percent Decrease Since March 2020 — Data Talk
Franco-Nevada Corporation (FNV) is currently at $114.48, down $10.49 or 8.39%
--Would be lowest close since March 26, 2024, when it closed at $113.82
--On pace for largest percent decrease since March 27, 2020, when it fell 8.5%
--Snaps a four day winning streak
--Down 11.23% month-to-date
--Up 3.31% year-to-date
--Down 31.86% from its all-time closing high of $168.01 on April 20, 2022
--Down 17.24% from 52 weeks ago (Aug. 16, 2023), when it closed at $138.33
--Down 20.64% from its 52-week closing high of $144.26 on Aug. 30, 2023
--Up 10.29% from its 52-week closing low of $103.80 on Dec. 12, 2023
--Traded as low as $113.95; lowest intraday level since March 27, 2024, when it hit $113.77
--Down 8.82% at today's intraday low; largest intraday percent decrease since Oct. 30, 2023, when it fell as much as 9.94%
All data as of 12:29:26 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
August 14, 2024 12:46 ET (16:46 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks